Last Updated: July 26, 2026

Details for Patent: 9,427,402

Name: Drug Patent Intelligence for US Patent 9427402
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,427,402 protect, and when does it expire?

Patent 9,427,402 protects MULPLETA and is included in one NDA.

This patent has fifteen patent family members in ten countries.

Summary for Patent: 9,427,402

Title:	Preparation for improving solubility of poorly soluble drug
Abstract:	The present invention relates to solubility improving preparation for enhancing the oral absorption of a poorly soluble drug, which is comprising (A) and (B);
Inventor(s):	Satoshi Sakuma, Hiroshi Ueda, Akira Mashimo, Hiroshi Murazato
Assignee:	Eddingpharm Hong Kong Co Ltd
Application Number:	US13/825,552
Patent Claim Types: see list of patent claims	Use; Process; Dosage form;

Drugs Protected by US Patent 9,427,402

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vancocin Italia	MULPLETA	lusutrombopag	TABLET;ORAL	210923-001	Jul 31, 2018		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,427,402

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2010-221000	Sep 30, 2010

PCT Information
PCT Filed	September 29, 2011	PCT Application Number:	PCT/JP2011/072355
PCT Publication Date:	April 05, 2012	PCT Publication Number:	WO2012/043709

International Family Members for US Patent 9,427,402

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	112013007364	⤷ Start Trial
Canada	2813147	⤷ Start Trial
China	103228277	⤷ Start Trial
European Patent Office	2623100	⤷ Start Trial
Spain	2949552	⤷ Start Trial
Japan	2014141518	⤷ Start Trial
Japan	5557146	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.